Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-08-2021 | Antibiotic | Brief Report

Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes

Authors: Sylvain Chawki, Aurélien Sokal, Marion Duprilot, Amandine Henry, Véronique Leflon-Guibout, Marie-Hélène Nicolas-Chanoine, Bruno Fantin, Victoire de Lastours

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2021

Abstract

With rising antibiotic resistance, alternatives to carbapenems are needed for acute cholangitis (AC). Temocillin reaches high biliary concentrations with limited impact on microbiota. We retrospectively included 140 AC episodes and assessed the efficacy of temocillin using microbiology susceptibility testing from blood cultures. Considering all bacteria collected by episode, resistance to temocillin, PIP/TAZ and 3GC occurred in 27/140 (26%), 32 (22.8%) and 31 (22%) episodes, respectively (p = 0.7). After documentation, temocillin could have spared PIP/TAZ or carbapenems in 14/26 and 4/11 episodes. Temocillin may constitute an alternative treatment after microbiological documentation by sparing carbapenems and/or PIP/TAZ, but not as an empirical therapeutic option.

Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G et al (2018) Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J. Hepato-Biliary-Pancreat. Sci. 25:41–54. https://doi.org/10.1002/jhbp.515CrossRef

Tagashira Y, Sakamoto N, Isogai T, Hikone M, Kosaka A, Chino R et al (2017) Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis: a retrospective cohort study. Clin Microbiol Infect Off. Publ Eur Soc Clin Microbiol Infect Dis 23:740–747. https://doi.org/10.1016/j.cmi.2017.02.027CrossRef

Sokal A, Sauvanet A, Fantin B, de Lastours V (2019) Acute cholangitis: diagnosis and management. J Visc Surg 156:515–525. https://doi.org/10.1016/j.jviscsurg.2019.05.007CrossRefPubMed

Gomi H, Takada T, Hwang T-L, Akazawa K, Mori R, Endo I et al (2017) Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepato-Biliary-Pancreat Sci 24:310–318. https://doi.org/10.1002/jhbp.452CrossRef

Gomi H, Solomkin JS, Takada T, Strasberg SM, Pitt HA, Yoshida M et al (2013) TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J. Hepato-Biliary-Pancreat. Sci. 20:60–70. https://doi.org/10.1007/s00534-012-0572-0CrossRef

Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ et al (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 15(50):133–164. https://doi.org/10.1086/649554CrossRef

WHO. WHO. Global action plan on antimicrobial resistance [Internet]. 2015;doi: http://apps.who.int/medicinedocs/documents/s21889en/s21889en.pdf

Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31. https://doi.org/10.1128/CMR.00079-17

Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS et al (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56–66. https://doi.org/10.1016/S1473-3099(18)30605-4CrossRefPubMedPubMedCentral

10.

Maudgal DP, Lanzini A, Northfield TC, Bridges C, Joseph AE (1985) Quantification of temocillin biliary excretion and gallbladder bile concentration in healthy subjects. Drugs 29(Suppl 5):146–150. https://doi.org/10.2165/00003495-198500295-00030CrossRefPubMed

11.

Poston GJ, Greengrass A, Moryson CJ (1985) Biliary concentrations of temocillin. Drugs 29(Suppl 5):140–145. https://doi.org/10.2165/00003495-198500295-00029CrossRefPubMed

12.

Livermore DM, Tulkens PM (2009) Temocillin revived. J Antimicrob Chemother 63:243–245. https://doi.org/10.1093/jac/dkn511CrossRefPubMed

13.

Alexandre K, Fantin B (2018) Pharmacokinetics and pharmacodynamics of temocillin. Clin Pharmacokinet 57:287–296. https://doi.org/10.1007/s40262-017-0584-7CrossRefPubMed

14.

Balakrishnan I, Koumaki V, Tsakris A (2019) Temocillin: is this the right momentum for its global use? Future Microbiol 14:81–83. https://doi.org/10.2217/fmb-2018-0316CrossRefPubMed

15.

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. www.eucast.org 2013;

16.

EUCAST_General_Consultation_on_temocillin_breakpoints_20191011.pdf [Internet]. [cited 2020 7];doi: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/2019/EUCAST_General_Consultation_on_temocillin_breakpoints_20191011.pdf

17.

Woerther P-L, Lepeule R, Burdet C, Decousser J-W, Ruppé É, Barbier F (2018) Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance? Int. J Antimicrob Agents 52:762–770. https://doi.org/10.1016/j.ijantimicag.2018.08.026CrossRef

18.

Alexandre K, Chau F, Guérin F, Massias L, Lefort A, Cattoir V et al (2016) Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli. J Antimicrob Chemother 71:1899–1904. https://doi.org/10.1093/jac/dkw066CrossRefPubMed

19.

Alexandre K, Soares A, Chau F, Fantin B, Caron F, Etienne M. Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates. J Antimicrob Chemother. 2019 1;74:1323–6. https://doi.org/10.1093/jac/dky569

20.

Laterre P-F, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S et al (2015) Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother 70:891–898. https://doi.org/10.1093/jac/dku465CrossRefPubMed

21.

Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B et al (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66:2628–2631. https://doi.org/10.1093/jac/dkr317CrossRefPubMed

Title: Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes
Authors: Sylvain Chawki
Aurélien Sokal
Marion Duprilot
Amandine Henry
Véronique Leflon-Guibout
Marie-Hélène Nicolas-Chanoine
Bruno Fantin
Victoire de Lastours
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Antibiotic
Carbapenem Antibiotic
Respiratory Microbiota
Cholangitis
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04158-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2021

Annual variations of Haemophilus influenzae carriage among Hajj pilgrims

Comparison of clinical characteristics and outcomes between respiratory syncytial virus and influenza-related pneumonia in China from 2013 to 2019

Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran

Incidence, clinical characteristics, risk factors and outcomes of meningoencephalitis in patients with COVID-19

Therapeutic efficacy of chitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin on airway inflammation in asthmatic mice

Molecular testing for H. pylori clarithromycin and quinolone resistance: a prospective Chinese study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage